Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $8.0 million.

  • Harmony Biosciences Holdings' Gains from Investment Securities rose 771.1% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 771.1%. This contributed to the annual value of $7.2 million for FY2024, which is 1331.15% up from last year.
  • According to the latest figures from Q3 2025, Harmony Biosciences Holdings' Gains from Investment Securities is $8.0 million, which was up 771.1% from $8.0 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Gains from Investment Securities registered a high of $21.1 million during Q4 2024, and its lowest value of $369000.0 during Q1 2023.
  • In the last 5 years, Harmony Biosciences Holdings' Gains from Investment Securities had a median value of $6.3 million in 2021 and averaged $6.5 million.
  • Per our database at Business Quant, Harmony Biosciences Holdings' Gains from Investment Securities crashed by 9385.56% in 2022 and then soared by 189526.37% in 2024.
  • Harmony Biosciences Holdings' Gains from Investment Securities (Quarter) stood at $2.0 million in 2021, then surged by 50.23% to $2.9 million in 2022, then skyrocketed by 297.21% to $11.7 million in 2023, then skyrocketed by 80.38% to $21.1 million in 2024, then tumbled by 62.13% to $8.0 million in 2025.
  • Its Gains from Investment Securities stands at $8.0 million for Q3 2025, versus $8.0 million for Q2 2025 and $2.2 million for Q1 2025.